Received Mar 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | T5D73 | — |
Adult dose to a pediatric patient; Adult dose to a pediatric patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult product administered to child in a 5-year-old patient who received HBV (Engerix B adult) (batch number T5D73) for prophylaxis. On 23-FEB-2026, the patient received Engerix B adult. On 23-FEB-2026, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: Adult dose to a pediatric patient) and overdose (Verbatim: Adult dose to a pediatric patient). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-FEB-2026 The patient under 20 years of age, received Engerix-B adult dose. The Vaccine Administration Facility was the same as Primary Reporter. This was 1 of 4 linked cases, reported by the same reporter.; Sender's Comments: US-GSK-US2026026564:Same reporter/Diffrent patient US-GSK-US2026AMR034516: US-GSK-US2026AMR034517: